<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02352896</url>
  </required_header>
  <id_info>
    <org_study_id>EPI743-13-023</org_study_id>
    <nct_id>NCT02352896</nct_id>
  </id_info>
  <brief_title>Long-Term Safety and Efficacy Evaluation of EPI-743 in Children With Leigh Syndrome</brief_title>
  <official_title>EPI743-13-023: Long-Term Safety and Efficacy Evaluation of EPI-743 in Children With Leigh Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edison Pharmaceuticals Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edison Pharmaceuticals Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      EPI-743 in Leigh syndrome subjects that participated in previous EPI743-12-002 study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To monitor the long-term safety and neurodevelopmental effects of EPI-743 on children who
      complete the EPI743-12-002 placebo controlled trial.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Long term effect of EPI743 on disease severity as measured by NPMDS</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of EPI743 on neurodevelopment as measured by Bayley or Wechsler Scales</measure>
    <time_frame>2 years</time_frame>
    <description>neurodevelopment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of EPI743 on neuromuscular function as assesed by Barry Albright Dystonia</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of EPI743 on Respiratory Function as measured by oxygen saturation</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of EPI743 on disease morbidity and mortality as measure by mortality, medical encounters and hospitallizations</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of EPI743 on Safety as measure by differences in adverse events</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">31</enrollment>
  <condition>Leigh Syndrome</condition>
  <arm_group>
    <arm_group_label>EPI-743</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EPI-743 administered at a dose of 15 mg/kg up to a total 200 mg three times daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPI-743</intervention_name>
    <description>EPI-743 is a quinone oxidation product of alpha tocotrienol</description>
    <arm_group_label>EPI-743</arm_group_label>
    <other_name>VincerinoneTM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of Leigh syndrome with genetic confirmation

          2. Completion of EPI743-12-002 protocol and initiation of treatment within 14 days of
             Month 12 Visit in EPI743-12-002 study

          3. Patient or Patient's guardian able to consent and comply with protocol requirements

          4. Continued abstention from supplements excluded in EPI743-12-002 study

          5. Continued abstention from BotoxÂ® and for the duration of the study

        Exclusion Criteria:

          1. Allergy to EPI-743 or sesame oil

          2. Allergy to vitamin E

          3. Clinical history of bleeding or abnormal baseline PT/PTT

          4. Hepatic insufficiency with LFTs greater than two times upper limit of normal

          5. Renal insufficiency requiring dialysis

          6. End stage cardiac failure

          7. Fat malabsorption syndromes precluding drug absorption

          8. Use of anticoagulant medications

          9. Participation in other clinical research studies/taking other experimental agents

         10. Participation in elective procedures that required sedation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce Cohen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Akron Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gregory Enns</name>
      <address>
        <city>Stanford University</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akron Children's Hospital</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2014</study_first_submitted>
  <study_first_submitted_qc>January 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2015</study_first_posted>
  <last_update_submitted>June 29, 2017</last_update_submitted>
  <last_update_submitted_qc>June 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leigh syndrome</keyword>
  <keyword>Mitochondrial disorders</keyword>
  <keyword>EPI743</keyword>
  <keyword>Vincerinone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leigh Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ubiquinone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

